Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PODD

Insulet Corporation

Healthcare | Medical - Devices

No licensed closing price on file for PODD. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$5.33

Insulet Corporation (NASDAQ: PODD) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 02:39 UTC.

What Insulet Corporation does

Insulet Corporation develops, manufactures, and sells continuous insulin delivery systems, primarily the Omnipod platform, which includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH, and Classic Omnipod for people with insulin-dependent diabetes. The company also manufactures pods for Amgen's Neulasta Onpro delivery system. Insulet addresses a significant market need, as diabetes is a chronic disease affecting millions globally, with insulin-dependent diabetes requiring continuous management throughout the day.

Summarized from Insulet Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$5.33
Return on equity16.31%
Debt/equity0.65

Revenue, margins & earnings

FY2021 Taxes & interest: $109MFY2021 Operating expenses: $626MFY2021 Cost of revenue: $347M$1.10BFY2021FY2022 Taxes & interest: $33MFY2022 Operating expenses: $768MFY2022 Cost of revenue: $500M$1.31BFY2022FY2023 Net income: $206MFY2023 Operating expenses: $940MFY2023 Cost of revenue: $537M$1.70BFY2023FY2024 Revenue: $2.07B — margin split not shown (non-operating gains)$2.07BFY2024FY2025 Net income: $247MFY2025 Taxes & interest: $227MFY2025 Operating expenses: $1.47BFY2025 Cost of revenue: $768M$2.71BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-05
  • 2026-10-05EVP & CFOTax withholding-1,882$246.1K
  • 2026-10-02DirectorAward141$18.4K
  • 2026-10-02DirectorAward178$23.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Insulet Corporation do?

Insulet Corporation develops, manufactures, and sells continuous insulin delivery systems, primarily the Omnipod platform, which includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH, and Classic Omnipod for people with insulin-dependent diabetes.

When did PODD last file with the SEC?

Insulet Corporation's most recent SEC filing on record is a 8-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:39 UTC. This page is also available as JSON at /api/data?ticker=PODD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PODD and 5,000+ tickers.

Create a free account — keep PODD
For your agent
GET /api/data?ticker=PODD

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt